Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States and Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.17|
|52 Week High||AU$0.17|
|52 Week Low||AU$0.51|
|1 Month Change||-29.29%|
|3 Month Change||-31.37%|
|1 Year Change||-50.70%|
|3 Year Change||-52.70%|
|5 Year Change||-81.58%|
|Change since IPO||-94.17%|
Recent News & Updates
|TTB||AU Healthcare||AU Market|
Return vs Industry: TTB underperformed the Australian Healthcare industry which returned 17.4% over the past year.
Return vs Market: TTB underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: TTB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: TTB's weekly volatility (10%) has been stable over the past year.
About the Company
Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States and Australia. It offers Total Brain, a neuroscience-based mental health and brain performance app. The company was formerly known as Brain Resource Limited and changed its name to Total Brain Limited in December 2018.
Total Brain Fundamentals Summary
|TTB fundamental statistics|
Is TTB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TTB income statement (TTM)|
|Cost of Revenue||AU$8.88m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.062|
|Net Profit Margin||-225.13%|
How did TTB perform over the long term?See historical performance and comparison
Is Total Brain undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TTB (A$0.18) is trading below our estimate of fair value (A$3.82)
Significantly Below Fair Value: TTB is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: TTB is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: TTB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TTB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TTB is good value based on its PB Ratio (1.3x) compared to the AU Healthcare industry average (2.2x).
How is Total Brain forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TTB is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: TTB is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TTB's is expected to become profitable in the next 3 years.
Revenue vs Market: TTB's revenue (55% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: TTB's revenue (55% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TTB's Return on Equity is forecast to be high in 3 years time (20.6%)
How has Total Brain performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TTB is currently unprofitable.
Growing Profit Margin: TTB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TTB is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare TTB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TTB is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: TTB has a negative Return on Equity (-46.25%), as it is currently unprofitable.
How is Total Brain's financial position?
Financial Position Analysis
Short Term Liabilities: TTB's short term assets (A$6.8M) exceed its short term liabilities (A$6.1M).
Long Term Liabilities: TTB has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: TTB's debt to equity ratio (23.7%) is considered satisfactory.
Reducing Debt: TTB's debt to equity ratio has reduced from 31.6% to 23.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TTB has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TTB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Total Brain current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TTB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TTB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TTB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TTB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TTB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Louis Gagnon has been Chief Executive Officer of Total Brain Limited (formerly known as Brain Resource Limited) since May 22, 2017 and has been its Managing Director since December 22, 2017. Mr. Gagnon...
CEO Compensation Analysis
Compensation vs Market: Louis's total compensation ($USD403.99K) is above average for companies of similar size in the Australian market ($USD301.38K).
Compensation vs Earnings: Louis's compensation has increased whilst the company is unprofitable.
Experienced Management: TTB's management team is considered experienced (3.7 years average tenure).
Experienced Board: TTB's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TTB insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.2%.
Total Brain Limited's employee growth, exchange listings and data sources
- Name: Total Brain Limited
- Ticker: TTB
- Exchange: ASX
- Founded: 2000
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$23.343m
- Shares outstanding: 133.39m
- Website: https://www.totalbrain.com
Number of Employees
- Total Brain Limited
- 15 Belvoir Street
- Surry Hills
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.